Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Redx Pharma's share price for the quarter that ended in Sep. 2023 was £0.26. Redx Pharma's Shares Outstanding (EOP) for the quarter that ended in Sep. 2023 was 334.91 Mil. Therefore, Redx Pharma's market cap for the quarter that ended in Sep. 2023 was £87.08 Mil.
Redx Pharma's quarterly market cap
declined
from Sep. 2022 (£189.22 Mil) to Mar. 2023 (£103.82 Mil) and
declined
from Mar. 2023 (£103.82 Mil) to Sep. 2023 (£87.08 Mil).
Redx Pharma's annual market cap
declined
from Sep. 2021 (£235.37 Mil) to Sep. 2022 (£189.22 Mil) and
declined
from Sep. 2022 (£189.22 Mil) to Sep. 2023 (£87.08 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Redx Pharma's Enterprise Value for Today is £57.94 Mil.
Redx Pharma Market Cap Historical Data
The historical data trend for Redx Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Redx Pharma's Market Cap
For the Biotechnology subindustry, Redx Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Redx Pharma's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Redx Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where Redx Pharma's Market Cap falls into.
Redx Pharma Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Redx Pharma's Market Cap for the fiscal year that ended in Sep. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Redx Pharma (LSE:REDX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Redx Pharma Market Cap Related Terms
Thank you for viewing the detailed overview of Redx Pharma's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Redx Pharma PLC is a United Kingdom-based biotechnology company focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases. Its product pipeline under development includes Porcupine Inhibitor, ROCK2 Selective Inhibitor, GI-targeted ROCK inhibitor, Pan-RAF Inhibitor, and others. The firm operates geographically in UK and Ireland. Revenue is generated from; Scientific programmes and research collaboration, Research collaboration and Research and preclinical development services. Redx is a clinical-stage biotechnology company focused on the discovery & development of novel, small-molecule, targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:REDX has been successfully added to your 